HAIFA, Israel, Sept. 7, 2011 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) announced today that animal studies it has conducted suggest that its PLacental eXpanded (PLX) cells are potentially effective in treating life threatening hematopoietic complications associated with Acute Radiation Syndrome (ARS).
